Results for tag: "Bronchiolitis Obliterans Syndrome Drug"

Bronchiolitis Obliterans Syndrome (BOS) is a rare and serious lung disease caused by an inflammatory response to inhaled toxins. It is characterized by the narrowing of the bronchioles, leading to difficulty breathing and other respiratory symptoms. Treatment for BOS is limited to supportive care, such as oxygen therapy, and medications to reduce inflammation and improve airway function. The BOS drug market is a small but growing segment of the respiratory drug market. It is composed of a variety of medications, including corticosteroids, bronchodilators, and immunosuppressants. These drugs are used to reduce inflammation, improve airway function, and reduce the risk of further damage to the lungs. The BOS drug market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as GlaxoSmithKline, AstraZeneca, and Novartis are all active in the BOS drug market, offering a range of medications to treat the condition. Other companies, such as Merck, Pfizer, and Sanofi, are also involved in the development of new treatments for BOS. Show Less Read more